Claims Vs. Reality: Why EHR Data Is The Game Changer For Life Sciences Success

The pharmaceutical industry is currently navigating a particularly difficult landscape shaped by a convergence of rising costs and diminishing financial returns. The expense of bringing a new drug to market has surged dramatically, now averaging over $2 billion—a figure that reflects a striking 15% increase in just the past year alone. At the same time, the return on investment (ROI) for new therapies has plummeted, hitting the lowest level recorded since such metrics began being tracked. In response to these challenges, the strategic use of high-quality real-world data (RWD) has become increasingly vital.

RWD offers life sciences companies a pathway to uncover operational efficiencies, enhance profitability, and accelerate the delivery of therapies to the patients who need them most. To truly gain a competitive edge, pharmaceutical companies must harness the full potential of comprehensive RWD, particularly data derived from electronic health records (EHRs). This richer, more nuanced data enables the generation of robust real-world evidence (RWE), which is essential for informed decision-making, regulatory support, and ultimately, the successful development and deployment of innovative therapies.